Skip to main content

Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting

Current TAP Partner


PHILADELPHIA, PA – May 26, 2022 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced two presentations including findings of its lead candidate, CT-0508, accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, June 3-7. The company will present the latest data from its landmark CT-0508 chimeric antigen receptor macrophage (CAR-M) trial for patients with advanced metastatic HER2 overexpressing solid tumors, reaffirming safety and feasibility of its proprietary engineered cell therapy platform. Clinical trial design for phase 1 study of adenovirally transduced autologous macrophages, a second CT-0508 study, was also accepted for presentation.

Both of the abstracts will be presented at the 2022 ASCO Annual Meeting in the “Developmental Therapeutics—Immunotherapy” poster session on June 5.

Press Release